An innovation-led biopharma advancing transformative therapies through translational science, strategic collaborations, and technology-enabled drug discovery.
Alixer Nexgen Therapeutics is a
next-generation biopharma organization focused on discovering and developing innovative therapies for diseases with significant unmet medical needs.
Driven by scientific rigor, translational research, and strategic global collaborations, Alixer integrates advanced biology, AI-enabled discovery, and biomarker-driven development to accelerate innovation.
As a wholly owned subsidiary of Alkem Laboratories Ltd, Alixer combines the strength of an established pharmaceutical legacy with an agile, future-focused innovation ecosystem.
Alixer operates through a collaborative and translational R&D model designed to bridge the gap between scientific discovery and clinical impact.
The organization partners with leading academic institutions, researchers, innovators, and global scientific ecosystems to identify novel therapeutic targets and accelerate development pathways.
By integrating scientific expertise, translational research, advanced analytics, and regulatory-aligned development strategies, Alixer synergizes development efficiency and scalable innovation.
Discovering and advancing next-generation therapies through cutting edge research.
Building strategic partnerships across academia and biopharma ecosystem.
Advancing therapies designed to address diseases with high unmet medical need and improving patient outcomes.
Leveraging data-driven approaches, advanced analytics, and AI-supported strategies to accelerate innovation.
As a wholly owned subsidiary of Alkem Laboratories Ltd, Alixer Nexgen Therapeutics combines the agility of a modern innovation-led biotech platform with the strength, credibility, and healthcare legacy of an established global pharmaceutical organization.
Alixer Nexgen is committed to accelerating scientific innovation through collaboration, translational excellence, and next-generation therapeutic development.
